|
| 36456359 | Current status of National Institutes of Health funding for thoracic surgeons in the United States: Beacon of hope or candle in the wind? | J Thorac Cardiovasc Surg | 2024 |
| 37584292 | Red cell distribution width as a new prognostic biomarker in refractory chronic graft-<i>versus</i>-host disease. | Haematologica | 2024 |
| 36810713 | Bridging Health Disparities: a Genomics and Transcriptomics Analysis by Race in Prostate Cancer. | J Racial Ethn Health Disparities | 2024 |
| 36456359 | Current status of National Institutes of Health funding for thoracic surgeons in the United States: Beacon of hope or candle in the wind? | J Thorac Cardiovasc Surg | 2024 |
| 37584292 | Red cell distribution width as a new prognostic biomarker in refractory chronic graft-<i>versus</i>-host disease. | Haematologica | 2024 |
| 36810713 | Bridging Health Disparities: a Genomics and Transcriptomics Analysis by Race in Prostate Cancer. | J Racial Ethn Health Disparities | 2024 |
| 36346688 | Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group. | Clin Cancer Res | 2023 |
| 36302175 | A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. | Clin Cancer Res | 2023 |
| 36302173 | Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. | Clin Cancer Res | 2023 |
| 36346688 | Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group. | Clin Cancer Res | 2023 |
| 35882475 | Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment. | Blood Adv | 2023 |
| 36208017 | Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel. | Cancer Med | 2023 |
| 35482927 | Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. | Blood Adv | 2023 |
| 37824137 | Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37684526 | Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease. | Bone Marrow Transplant | 2023 |
| 37682953 | Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis. | PLoS One | 2023 |
| 37474729 | Predictors and significance of kidney dysfunction in patients with chronic graft-versus-host disease. | Bone Marrow Transplant | 2023 |
| 37398992 | Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma. | Clin Cancer Res | 2023 |
| 36705597 | Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. | Clin Cancer Res | 2023 |
| 37394115 | Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure. | Transplant Cell Ther | 2023 |
| 37134294 | Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. | Oncologist | 2023 |
| 37011643 | Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial. | Lancet Haematol | 2023 |
| 36754451 | Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. | J Immunother Cancer | 2023 |
| 37389844 | Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R. | Blood Adv | 2023 |
| 37115514 | Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. | Neuro Oncol | 2023 |
| 37486616 | A comprehensive analysis of adverse events in the first 30Â days of phase 1 pediatric CAR T-cell trials. | Blood Adv | 2023 |
| 37486616 | A comprehensive analysis of adverse events in the first 30Â days of phase 1 pediatric CAR T-cell trials. | Blood Adv | 2023 |
| 37684526 | Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease. | Bone Marrow Transplant | 2023 |
| 37824137 | Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37682953 | Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis. | PLoS One | 2023 |
| 35482927 | Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. | Blood Adv | 2023 |
| 37394115 | Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure. | Transplant Cell Ther | 2023 |
| 37389844 | Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R. | Blood Adv | 2023 |
| 37115514 | Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. | Neuro Oncol | 2023 |
| 37011643 | Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial. | Lancet Haematol | 2023 |
| 37134294 | Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. | Oncologist | 2023 |
| 37474729 | Predictors and significance of kidney dysfunction in patients with chronic graft-versus-host disease. | Bone Marrow Transplant | 2023 |
| 37398992 | Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma. | Clin Cancer Res | 2023 |
| 36705597 | Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. | Clin Cancer Res | 2023 |
| 36754451 | Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. | J Immunother Cancer | 2023 |
| 36208017 | Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel. | Cancer Med | 2023 |
| 36302175 | A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. | Clin Cancer Res | 2023 |
| 36302173 | Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. | Clin Cancer Res | 2023 |
| 35882475 | Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment. | Blood Adv | 2023 |
| 34767461 | Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. | J Clin Oncol | 2022 |
| 35834728 | Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. | Blood Adv | 2022 |
| 35747850 | Determinants and Clinical Significance of Musculoskeletal Symptoms in Patients With Chronic Graft-Versus-Host Disease. | Hemasphere | 2022 |
| 35939781 | The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. | Blood Adv | 2022 |
| 35605184 | CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. | Blood | 2022 |
| 35535581 | A phase II trial of the super-enhancer inhibitor Minnelideâ¿¢ in advanced refractory adenosquamous carcinoma of the pancreas. | Future Oncol | 2022 |